High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response

mTOR inhibition decreases SOX2-SOX9 mediated glioma stem cell activity and temozolomide resistance

(2016) Laura Garros-Regulez et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer

(2016) R. Rincon et al.   MOLECULAR CANCER THERAPEUTICS

DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non-Small Cell Lung Cancers

(2015) Y.-C. Lin et al.   CLINICAL CANCER RESEARCH

Glioblastoma Stem Cells Respond to Differentiation Cues but Fail to Undergo Commitment and Terminal Cell-Cycle Arrest

(2015) Helena Carén et al.   Stem Cell Reports

Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplay

(2014) FRANCESCO MARAMPON et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience

(2014) Pavel Bezecny   MEDICAL ONCOLOGY

The epidemiology of glioma in adults: a "state of the science" review

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells

(2013) Ming-Tsang Chiao et al.   Autophagy

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis

(2013) Kantima Leelahavanichkul et al.   Molecular Oncology

Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism

(2013) Beatriz Gil-Araujo et al.   Molecular Oncology

Therapeutic Strategies Targeting Glioblastoma Stem Cells

(2013) Estefania Carrasco-Garcia et al.   Recent Patents on Anti-Cancer Drug Discovery

Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells

(2013) Atsushi Sato et al.   Stem Cell Research

Tumor-Specific Activation of the C-JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53-Dependent Manner

(2013) Chunyu Gu et al.   STEM CELLS

Therapeutic Effect of γ-Secretase Inhibition in KrasG12V-Driven Non-Small Cell Lung Carcinoma by Derepression of DUSP1 and Inhibition of ERK

(2012) Antonio Maraver et al.   CANCER CELL

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

(2012) G. J. Kitange et al.   CLINICAL CANCER RESEARCH

Dual-specificity MAP kinase phosphatases (MKPs)

(2012) Christopher J. Caunt et al.   FEBS Journal

Clonal evolution in cancer

(2012) Mel Greaves et al.   NATURE

c-Jun N-terminal kinase has a pivotal role in the maintenance of self-renewal and tumorigenicity in glioma stem-like cells

(2012) C-H Yoon et al.   ONCOGENE

DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer

(2010) V Moncho-Amor et al.   ONCOGENE

Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

(2010) Jun Sunayama et al.   STEM CELLS

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens

(2009) Steven M. Pollard et al.   Cell Stem Cell

Mitogen-Activated Protein Kinase Phosphatase-1 in Human Breast Cancer Independently Predicts Prognosis and Is Repressed by Doxorubicin

(2009) F. Rojo et al.   CLINICAL CANCER RESEARCH

Proinflammatory Mediators Upregulate Snail in Head and Neck Squamous Cell Carcinoma

(2009) M. A. St. John et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY